HBV Cure Initiatives: Science in Action, An Expert Review of Current Data
Activity Summary:
HBV is a most common causes of liver cirrhosis and HCC. Curing persons with HBV infection remains elusive, despite the availablility of effective antiviral therapy. However, the urgency for an HBV cure remains an active area of research. This program will discuss key research advances in the strategies to HBV cure, pros and cons of withdrawal of therapy, and novel antiviral/immunomodulatory therapies.
Dr. Nezam Afdhal and Dr. Daryl Lau will lead each of the 15-minute segment presentations with downloadable, supporting PowerPoint slides. Each segment will be available for .25 AMA/ANCC/ACPE credit/contact hour based on confirmed participation and the completion of an evaluation and post-test.
Faculty:Nezam Afdhal, MD, DSc and Daryl Lau, MD, MPH
Accreditation Type:Expired Activity
Launch Date:January 4, 2022
Release Date:December 16, 2021
Expiration Date: December 31, 2022
Estimated Time to Complete Activity:Informational Activity